Pharmaceutical - Pharmaceutical, Northern Europe

Filter

Popular Filters

1 to 25 of 64 results

IQWiG finds added benefit for Novo Nordisk’s NovoEight not proven

23-04-2014

In an early benefit assessment under the German Act on the Reform of the Market for Medicinal Products…

GermanyHematologyNorthern EuropeNovo NordiskNovoEightPharmaceuticalPricingRegulation

UK’s NICE rejects use of Roche’s Kadcyla for breast cancer on NHS

23-04-2014

UK drugs watchdog the National Institute for Health and Care Excellence (NICE) has today issued preliminary…

KadcylaNorthern EuropeOncologyPharmaceuticalPricingRegulationRocheUK

UK NICE recommends Giotrif and Velcade, but says “no” to added use of Alimta

23-04-2014

People in England and Wales with lung cancer whose tumors test positive for a mutation will now have…

AlimtaBoehringer IngelheimEli LillyGiotrifJohnson & JohnsonNorthern EuropeOncologyPharmaceuticalPricingRegulationUKVelcade

Novartis appoints Jeff George as Division Head, Alcon and Richard Francis as Division Head, Sandoz

Novartis appoints Jeff George as Division Head, Alcon and Richard Francis as Division Head, Sandoz

22-04-2014

Swiss drug major Novartis has announced the appointment of Jeff George as Division Head of Alcon and…

AlconBoardroomNorthern EuropeNovartisPharmaceuticalSandoz

French competition authority investigating Roche and Novartis over Lucentis marketing

10-04-2014

Following similar recent action by the equivalent Italian body, the French competition authority is launching…

AvastinBevacizumabFranceItalyLegalLucentisMarkets & MarketingMedicineNorthern EuropeNovartisOphthalmicsPharmaceuticalPharmacologyRocheUSD

GSK’s Tafinlar also no added benefit over vemurafenib, says IQWiG

GSK’s Tafinlar also no added benefit over vemurafenib, says IQWiG

09-04-2014

In an early benefit assessment under the German Act on the Reform of the Market for Medicinal Products…

GermanyGlaxoSmithKlineNorthern EuropeOncologyPharmaceuticalPricingRegulationTafinlarvemurafenib

Safinamide marketing application submitted to Swissmedic

07-04-2014

Italian drug developer Newron Pharmaceuticals and its partner, family-owned Italian drugmaker Zambon…

Markets & MarketingNeurologicalNewron PharmaNorthern EuropePharmaceuticalRegulationsafinamideZambon

UK’s NICE reverses negative decision on Roche’s Tarceva for NSCLC

04-04-2014

Following a consultation period, the UK drug watchdog the National Institute for Health and Care Excellence…

Northern EuropeOncologyPharmaceuticalPricingRegulationRocheTarcevaUK

Germany’s IQWiG views Xofigo, Kadcyla and Eviplera

03-04-2014

In an early benefit assessment under the Act on the Reform of the Market for Medicinal Products, the…

Anti-viralsBayerEvipleraGermanyGilead SciencesKadcylaNorthern EuropeOncologyPharmaceuticalPricingRegulationRocheXofigo

UK Pharma moves on transparency of financial relationships with health professionals

03-04-2014

The UK’s pharmaceutical industry today announced another step towards greater transparency by revealing…

FinancialNorthern EuropePharmaceuticalResearchUK

AstraZeneca and MRC to create new discovery center in Cambridge

AstraZeneca and MRC to create new discovery center in Cambridge

31-03-2014

Anglo-Swedish drug major AstraZeneca and the UK Medical Research Council (MRC) have entered into a collaboration…

AstraZenecaNorthern EuropePharmaceuticalResearchUK

UK’s NICE does not recommend Janssen’s Stelara for psoriatic arthritis

UK’s NICE does not recommend Janssen’s Stelara for psoriatic arthritis

28-03-2014

Final draft guidance from the UK health care costs watchdog the National Institute for Health and Care…

Anti-Arthritics/RheumaticsJanssenJohnson & JohnsonNorthern EuropePharmaceuticalPricingRegulationStelara InjectionUK

Novartis’ ceritinib improves survival in patients with non-small cell lung cancer

Novartis’ ceritinib improves survival in patients with non-small cell lung cancer

27-03-2014

Swiss drug major Novartis has published clinical trial results showing the investigational compound LDK378…

LDK378Northern EuropeNovartisOncologyPharmaceuticalResearch

UK regulator keeps IMS pharmaceutical data undertakings in place

UK regulator keeps IMS pharmaceutical data undertakings in place

26-03-2014

The UK Competition Commission (CC) has decided against varying or removing undertakings which restrict…

IMS HealthNorthern EuropePharmaceuticalRegulationUK

NICE final guidance again rejects Sanofi’s Zaltrap for colorectal cancer

25-03-2014

UK drugs watchdog the National Institute for Health and Care Excellence (NICE), today issued final guidance…

Northern EuropeOncologyPharmaceuticalPricingRegulationSanofiUKZaltrap

UK’s NICE unable to give the go ahead to new prostate cancer drug Xofigo

24-03-2014

The UK drugs watchdog the National Institute for Health and Care Excellence (NICE) has issued new draft…

BayerNorthern EuropeOncologyPharmaceuticalPricingRegulationUKXofigo

UK about turn, as JCVI now recommends meningitis B vaccination for infants

21-03-2014

The UK’s Joint Committee on Vaccination and Immunization has recommended that the meningitis B vaccine…

BexseroNorthern EuropeNovartisPharmaceuticalRegulationUKVaccines

UK NICE backs Janssen’s Velcade for multiple myeloma

UK NICE backs Janssen’s Velcade for multiple myeloma

21-03-2014

In new draft guidance published today, UK drugs watchdog the National Institute for Health and Care Excellence…

JanssenJohnson & JohnsonNorthern EuropeOncologyPharmaceuticalPricingRegulationUKVelcade

Takeda appoints Giles Platford as Head of Emerging Markets

Takeda appoints Giles Platford as Head of Emerging Markets

19-03-2014

Japan’s largest drugmaker Takeda Pharmaceutical (TYO: 4502) has announced the appointment of Giles…

BoardroomNorthern EuropePharmaceuticalTakeda Pharma GmbH

Merck Serono appoints Meeta Gulyani as head of Strategy and Global Franchises

Merck Serono appoints Meeta Gulyani as head of Strategy and Global Franchises

19-03-2014

Merck Seron has announced the appointment of Meeta Gulyani to the position of Head of Strategy and Global…

GermanyMerck SeronoNorthern EuropePharmaceuticalUSA

Added benefit for non-pre-treated Yervoy patients in advanced melanoma not proven, says IQWiG

Added benefit for non-pre-treated Yervoy patients in advanced melanoma not proven, says IQWiG

19-03-2014

The German Institute for Quality and Efficiency in Health Care (IQWiG) has re-assessed the added benefit…

Bristol-Myers SquibbGermanyNorthern EuropeOncologyPharmaceuticalPricingRegulationYervoy

NICE draft guidance recommends Boehringer Ingelheim’s Giotrif

NICE draft guidance recommends Boehringer Ingelheim’s Giotrif

17-03-2014

UK drugs watchdog the National Institute for Health and care Excellence (NICE) this morning issued new…

Boehringer IngelheimGiotrifNorthern EuropeOncologyPharmaceuticalPricingRegulationUK

Undervaluing new medicines threatens patient wellbeing and economic growth; report

Undervaluing new medicines threatens patient wellbeing and economic growth; report

14-03-2014

Innovative medicines and other new therapies have extended life expectancy by some 10 years since the…

HealthcareNorthern EuropePharmaceuticalPricingRegulationUK

UK plans for early access to medicines scheme

UK plans for early access to medicines scheme

14-03-2014

Severely ill patients in the UK, and those with rare debilitating conditions, could be given new medicines…

HealthcareNorthern EuropePharmaceuticalRegulationUK

1 to 25 of 64 results

Parexel

Parexel

Back to top